Perflutren Lipid Microsphere Intravenous Suspension
Locally Advanced Pancreatic Ductal Adenocarcinoma
Flemming ForsbergPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Locally Advanced Pancreatic Ductal Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
POLO-LIKE KINASE 1 INHIBITOR NMS-1286937 OHSU Knight Cancer Institute | Phase 2 | B |
Cobimetinib University Health Network, Toronto | Phase 2 | B |
Licsbr West China Hospital | Phase 2 | CCC |
Losartan Fox Chase Cancer Center | Phase 1 | CCC |
Xer-001 Xerient Pharma | Phase 1/2 | CC |
View all 12 →
Same molecule, other indications
Perflutren Lipid Microsphere Intravenous Suspension is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →